Introducing “HEDGE”: sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer. (2026). Archivio Italiano Di Urologia E Andrologia, 98(3). https://doi.org/10.4081/aiua.2026.15738